CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes.

CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes.
复制标题

DOI:
10.1038/srep34310
复制
发表时间:
2016-09-27
期刊:
影响因子:
4.6
通讯作者:
Wong SC
Wong SC
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Yeap WH;Wong KL;Shimasaki N;Teo EC;Quek JK;Yong HX;Diong CP;Bertoletti A;Linn YC;Wong SC

文献摘要

参考文献

被引文献

相似文献

抗体依赖性细胞毒性 (ADCC) 是由表达表面 Fcγ 受体 (FcγR) 的免疫细胞针对抗体包被的细胞(例如病毒感染或转化的细胞)发挥的。 CD16(FcγRIIIA)对于 NK 细胞的 ADCC 至关重要,并且也由人类血液单核细胞亚群表达。我们发现人类表达 CD16− 的单核细胞具有广泛的 ADCC 能力,并且可以在特异性抗体存在的情况下杀死癌细胞系、原代白血病细胞和乙型肝炎病毒感染的细胞。与靶细胞结合的抗体与单核细胞上的 CD16 结合,激活 β2-整合素并诱导 TNFα 分泌。反过来,这会诱导靶细胞上的 TNFR 表达,使它们容易受到 TNFα 介导的细胞死亡的影响。使用 TLR 激动剂、DAMP 或细胞因子(例如 IFNγ)治疗可进一步增强 ADCC。缺乏CD16的单核细胞不发挥ADCC作用,但在通过细胞因子刺激或瞬时转染诱导CD16表达后获得了这种特性。值得注意的是,白血病患者的 CD16+ 单核细胞也发挥了有效的 ADCC 作用。因此,CD16+单核细胞是 ADCC 的重要效应器,表明这一特性在癌症和传染病的细胞疗法中得到进一步发展。
Antibody-dependent cellular cytotoxicity (ADCC) is exerted by immune cells expressing surface Fcγ receptors (FcγRs) against cells coated with antibody, such as virus-infected or transformed cells. CD16, the FcγRIIIA, is essential for ADCC by NK cells, and is also expressed by a subset of human blood monocytes. We found that human CD16− expressing monocytes have a broad spectrum of ADCC capacities and can kill cancer cell lines, primary leukemic cells and hepatitis B virus-infected cells in the presence of specific antibodies. Engagement of CD16 on monocytes by antibody bound to target cells activated β2-integrins and induced TNFα secretion. In turn, this induced TNFR expression on the target cells, making them susceptible to TNFα-mediated cell death. Treatment with TLR agonists, DAMPs or cytokines, such as IFNγ, further enhanced ADCC. Monocytes lacking CD16 did not exert ADCC but acquired this property after CD16 expression was induced by either cytokine stimulation or transient transfection. Notably, CD16+ monocytes from patients with leukemia also exerted potent ADCC. Hence, CD16+ monocytes are important effectors of ADCC, suggesting further developments of this property in the context of cellular therapies for cancer and infectious diseases.
DOI: 10.1007/s00251-002-0486-0
发表时间: 2002-10-01
期刊: IMMUNOGENETICS
影响因子: 3.2
作者:
Mechetina, LV;Najakshin, AM;Taranin, AV
通讯作者: Taranin, AV
DOI: 10.5114/ceji.2012.32725
发表时间: 2012-01-01
影响因子: 1.3
作者:
Eljaszewicz, Andrzej;Jankowski, Michal;Zegarski, Wojciech
通讯作者: Zegarski, Wojciech
DOI: 10.1073/pnas.1014515107
发表时间: 2010-11-09
影响因子: 11.1
作者:
Nimmerjahn, Falk;Lux, Anja;Ravetch, Jeffrey V.
通讯作者: Ravetch, Jeffrey V.
DOI: 10.1111/j.1365-2249.2011.04321.x
发表时间: 2011-04-01
影响因子: 4.6
作者:
Feng, A-L.;Zhu, J-K.;Qu, X.
通讯作者: Qu, X.
DOI: 10.1200/jco.2008.18.0463
发表时间: 2009-03-01
影响因子: 45.3
作者:
Bibeau, Frederic;Lopez-Crapez, Evelyne;Boissiere-Michot, Florence
通讯作者: Boissiere-Michot, Florence